CD47 Blocker in Patients With Relapsed or Refractory Hematologic Malignancies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 1 Study of the CD47 Blocker TTI-621 in Patients With Relapsed or Refractory Hematologic Malignancies
Clin. Cancer Res 2021 Jan 15;[EPub Ahead of Print], SM Ansell, M Maris, AM Lesokhin, R Chen, IW Flinn, A Sawas, MD Minden, D Villa, MM Percival, AS Advani, JM Foran, S Horwitz, M Mei, J Zain, KJ Savage, C Querfeld, OE Akilov, LD Johnson, T Catalano, PS Petrova, RA Uger, EL Sievers, A Milea, K Roberge, Y Shou, OA O'ConnorFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.